Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Liminatus Pharma Inc. (LIMN) announced plans to establish a subsidiary called "American BNB Strategy" to invest up to $500 million in BNB coin, the native token of the Binance ecosystem.
The preclinical-stage biopharmaceutical company said it will raise and deploy the funds in phases for long-term investments in BNB coin. The initiative follows an internal review of blockchain-integrated financial strategies conducted over recent weeks.
Chief Executive Officer Chris Kim stated that BNB coin was selected due to its technology, global user base, and features such as Launchpool participation and staking models. The company plans to use custody infrastructure provided by Ceffu, an entity within the BNB ecosystem, for security and operational integrity.
Liminatus emphasized it remains committed to its core business of developing cancer therapeutics and pancreatic cancer diagnostics. The company characterized the digital asset expansion as supporting long-term growth and shareholder value.
The company described the move as rare for a traditional biopharmaceutical company and suggested it could set a precedent for other Nasdaq-listed companies entering the digital asset economy.
Liminatus is currently engaged in a capital raise process with placement agent Digital Offering. The board is reviewing and finalizing approval for the initiative, which remains subject to regulatory clearance and market conditions.
The company develops immunotherapies for cancer patients and is advancing a pipeline of therapies targeting cancer antigens and tumor-specific immune responses.